Application of remidazolam toluenesulfonate intravenous anesthesia in outpatient hysteroscopic surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063983

Enrollment

Unknown

Registered

2022-09-22

Start date

2022-09-23

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Rimazole group:Remidazolam toluenesulfonate intravenous general anesthesia

Propofol group:Propofol intravenous general anesthesia

Eligibility

Sex/Gender

Female

Age

19 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. All patients (females aged 19-55 years) met the requirements for hysteroscopic surgery without contraindications of narcotic drugs, and were classified as ASA grade I to II; 2. The patient has no mental disease or other organic diseases; 3. Patients were informed of this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with abnormal coagulation function; 2. Patients taking opioids and sedatives for a long time; 3. Patients who need intubation and general anesthesia due to illness or surgery; 4. Lactating patients and special groups with intellectual disabilities.

Design outcomes

Primary

Measure	Time frame
Vital signs;	—

Secondary

Measure	Time frame
Adverse reactions;PICU stay time;Recovery time;Postoperative pain;	—

Countries

China

Contacts

Public ContactTu Yuanyan

Dongguan Maternal and Child Health Hospital

jxtuyuan@sina.com+86 13729990829

Outcome results